Chemomab Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-13.95	-24.22	-27.65	-12.48	-5.95
Depreciation & Amortization	0.05	0.07	0.06	0.03	0.02
Stock-Based Compensation	0.62	1.49	3.21	2.02	0.13
Change in Accounts Receivable	-0.49	0.9	-0.06	-2.06	-0.1
Change in Accounts Payable	0.15	-1.17	0.35	1.18	0.07
Change in Other Net Operating Assets	-1.77	-0.68	3.72	-1.07	0.59
Operating Cash Flow	-15.39	-23.61	-20.37	-12.37	-5.24
Capital Expenditures	-	-0	-0.07	-0.24	-0.04
Sale of Property, Plant & Equipment	-	-	-	1	-
Investment in Securities	2.3	15.88	19.6	-45.95	-0.02
Other Investing Activities	-	-	-	0	-
Investing Cash Flow	2.3	15.88	19.53	-45.19	-0.06
Issuance of Common Stock	9.87	3.5	0.41	58.65	1.25
Repurchase of Common Stock	-	-	-1.22	-	-
Other Financing Activities	-	-	-	2.43	-
Financing Cash Flow	9.87	3.5	-0.81	61.07	4.75
Net Cash Flow	-3.22	-4.23	-1.65	3.51	-0.55
Free Cash Flow	-15.39	-23.61	-20.44	-12.61	-5.28
Free Cash Flow Per Share	-3.43	-8.04	-7.18	-4.86	-3.09
Cash Income Tax Paid	-	-0.19	-0.35	-	-
Levered Free Cash Flow	-10.86	-15.49	-10.87	-6.07	-2.56
Unlevered Free Cash Flow	-10.86	-15.49	-10.87	-6	-2.56
Change in Working Capital	-2.11	-0.95	4.01	-1.95	0.56

Updated Nov 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q